Investigational drug · Phase 3
Rifaximin SSD
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatic Encephalopathy.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "Rifaximin SSD"
First trial start
2022
Apr 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rifaximin SSD", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatic Encephalopathy
Largest trials
Live from ClinicalTrials.gov: studies naming "Rifaximin SSD" as an intervention, largest first.
- Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT05071716 · 524 participants · Start Apr 7, 2022 · Primary completion Dec 23, 2025
Drug: Rifaximin SSD; Placebo · For: Hepatic Encephalopathy
Sites: Dothan, Alabama; Chandler, Arizona; Peoria, Arizona · 150 sites in all
- Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With CirrhosisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT05297448 · 517 participants · Start Aug 3, 2022 · Primary completion Feb 24, 2026
Drug: Rifaximin SSD; Placebo · For: Hepatic Encephalopathy
Sites: Homewood, Alabama; Chandler, Arizona; Sun City, Arizona · 188 sites in all
- Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver CirrhosisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01904409 · 420 participants · Start Jun 2013 · Primary completion Jun 2015
Drug: Placebo; Rifaximin SSD 40 mg IR tablet and 4 more · For: Liver Cirrhosis
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 120 sites in all
Bausch Health Americas, Inc.Industry
NCT03515044 · 71 participants · Start Sep 13, 2018 · Primary completion Mar 12, 2020
Drug: 40 mg Rifaximin SSD once daily; 40 mg Rifaximin SSD twice daily and 3 more · For: Overt Hepatic Encephalopathy
Sites: Corona del Mar, California; Los Angeles, California; San Francisco, California · 34 sites in all
- Rifaximin SSD in Dementia TrialRecruiting
Jasmohan BajajFederal agency
NCT06718686 · 20 participants (planned) · Start Dec 30, 2024 · Primary completion Oct 30, 2027
Drug: Rifaximin SSD 40 mg IR tablet; Placebo · For: Dementia Alzheimer Type; Dementia Associated With Cerebrovascular Disease
Sites: Richmond, Virginia
David E. Kaplan, MD MScFederal agency
NCT01951209 · 13 participants · Start Nov 17, 2016 · Primary completion Nov 17, 2016
Drug: Rifaximin; Placebo · For: Liver Cirrhosis; Chronic Hepatitis C
Sites: Philadelphia, Pennsylvania
Philip KernAcademic, hospital or other
NCT02124512 · 12 participants · Start Mar 2015 · Primary completion May 31, 2019
Drug: Rifaximin SSD · For: Obese; Insulin Resistance; Metabolic Syndrome
Sites: Lexington, Kentucky
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.